LLY
StockEli Lilly and Co
- HQ
- US
- Sector
- Pharmaceuticals
- Issued
- 1985-01-13
- Shares out.
- 942M
Performance
4 d agoKey statistics
4 d ago- Market cap
- $1.06T
- Enterprise value
- $1.10T
- P/E (TTM)
- 41.85
- Forward P/E
- 24.92
- P/E (annual)
- 51.25
- PEG
- 1.29
- P/B
- 38.29
- P/S (TTM)
- 14.64
- P/S (annual)
- 16.23
- EV / EBITDA
- 32.65×
- EV / Revenue
- 15.17×
- EPS (TTM)
- $28.15
- EPS (annual)
- $22.95
- Basic EPS (TTM)
- $28.15
- Book value / share
- $28.09
- Gross margin
- 82.83%
- Operating margin
- 43.63%
- Net margin
- 34.99%
- Return on equity (ROE)
- 101.31%
- Return on assets (ROA)
- 22.73%
- Return on investment (ROI)
- 37.71%
- EBITDA / share
- $37.37
- Revenue / share (TTM)
- $80.64
- Revenue growth (TTM YoY)
- +47.44%
- Revenue growth (Q YoY)
- +55.55%
- EPS growth (TTM YoY)
- +128.83%
- Dividend yield (indicated)
- 0.61%
- Dividend yield (TTM)
- 0.53%
- Dividend / share (TTM)
- $5.91
- Payout ratio
- 22.10%
- Current ratio
- 1.58
- Quick ratio
- 0.78
- Debt / equity
- 1.60
- LT debt / equity
- 1.54
- Beta
- 0.53
- Volatility (3M)
- 37.23%
Analyst ratings
4 d agoEarnings
4 d agoRelated news
4 d ago- Yahoo·4 d agocompanyEli Lilly (LLY) Reports Positive Phase 1b Verve-102 Study Results
Eli Lilly and Company (NYSE:LLY) is one of the 12 Most Profitable Stocks to Invest In. On May 25, 2026, Eli Lilly and Company (NYSE:LLY) announced positive Phase 1b Heart-2 study results for Verve-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood […]
- Yahoo·4 d agocompanyWhy Eli Lilly (LLY) Stock Is Trading Up Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the afternoon session after CVS restored Zepbound as a co-preferred option and simultaneously added Lilly's new oral obesity pill Foundayo, making Eli Lilly's full obesity medication portfolio accessible to all three of America's largest pharmacy benefit managers for the first time.
- Yahoo·4 d agocompanyEli Lilly Jumps as CVS Expands Weight-Loss Drug Coverage
The change could improve patient access and support future sales growth.
- Yahoo·4 d agocompanyCVS Restores Coverage for Lilly's Zepbound
The move gives patients broader access to Lilly's obesity drugs and strengthens competition with Novo Nordisk.
- Yahoo·4 d agocompanyLilly Presses Ahead As $529 Billion Drug Pricing Fight Looms
Lilly will continue global launches despite MFN pricing uncertainty, Japan price cuts, and rising obesity-drug competition.
- Yahoo·4 d agocompany2 Mega-Cap Stocks on Our Buy List and 1 We Find Risky
Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less room for explosive growth as scale works against them.
- Yahoo·4 d agocompanyEli Lilly Expands Vaccine Push with Three Acquisitions, Reuters Reports
Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Reddit Stocks to Buy According to Billionaires. On May 26, Reuters reported that Eli Lilly and Company (NYSE:LLY) plans to acquire three vaccine developers in deals worth up to $3.8 billion combined, marking a deeper push into infectious disease prevention. The US drugmaker said […]
- Yahoo·4 d agocompanyS&P 500, Nasdaq Rise to Another Record. Software Strikes Back.
The stock market rode a big rally in software stocks to fresh highs on Thursday despite another hot inflation report. The Nasdaq gained 0.9%. The Dow rose 25 points to post a slight gain and eke out a fresh record, too.
